MIMEDX GROUP, INC. - 10-Q Summary (Q2 2026)
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. MiMedx Group, Inc. is a healthcare company focused on wound care, burn, and surgical products. The company operates as a single segment and is a large accelerated filer. As of July 23, 2026, there were 145,760,468 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q2 2026 | Q2 2025 | YTD 2026 | YTD 2025 |
|---|---|---|---|---|
| Net Sales | $64.4 million | $98.6 million | $123.4 million | $186.8 million |
| Gross Profit | $44.4 million | $79.9 million | $86.0 million | $151.6 million |
| Gross Margin | 69.0% | 81.1% | 69.7% | 81.1% |
| Operating Income (Loss) | $(18.5) million | $12.4 million | $(34.5) million | $20.6 million |
| Net Income (Loss) | $(14.8) million | $9.6 million | $(25.7) million | $16.6 million |
| Diluted EPS | $(0.10) | $0.06 | $(0.17) | $0.11 |
| Cash and Equivalents | $135.8 million | (Balance Sheet: Dec 31, 2025: $166.1 million) | ||
| Long-Term Debt | $15.7 million | (Balance Sheet: Dec 31, 2025: $16.5 million) | ||
| Operating Cash Flow (YTD) | $(8.1) million | $19.7 million | N/A |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 34.7% year-over-year in Q2 2026. This was driven by a 61.1% drop in Wound product sales due to Medicare reimbursement changes effective January 1, 2026. Conversely, Surgical sales grew 15.1%.
- Profitability Shift: The company reported a net loss of $14.8 million in Q2 2026, compared to net income of $9.6 million in Q2 2025. Gross margins compressed from 81.1% to 69.0% due to lower Wound pricing and higher manufacturing costs.
- Expense Management: SG&A expenses decreased 6.8% year-over-year due to cost reduction initiatives and a reduction-in-force. However, bad debt expense increased significantly ($5.0 million in Q2) due to credit deterioration of legacy customers.
- Cash Flow: Operating cash flow turned negative, using $8.1 million YTD 2026 compared to providing $19.7 million YTD 2025, largely due to lower collections and severance payments.
Guidance, Outlook, and Risks
- Strategic Priorities: Management is focusing on expanding the Surgical portfolio, launching new products, and executing cost reduction initiatives. Surgical sales have shown six consecutive quarters of double-digit growth.
- Capital Allocation: The company repurchased approximately $12.9 million of common stock in Q2 2026. $87.3 million remains available under the $100 million repurchase plan authorized in February 2026.
- Subsequent Events (Acquisition): On July 29, 2026, the company agreed to acquire Sanara MedTech Inc. for an enterprise value of approximately $350 million ($302 million cash + 4.4 million shares). Financing is secured via a $300 million senior secured term loan from Hayfin Capital Management.
- Debt Repayment: The company intends to prepay the remaining $17.3 million balance of its Citizens Term Loan on July 30, 2026.
- Risks: Key risks include the ongoing impact of Medicare reimbursement changes on Wound products, the outcome of pending litigation (specifically regarding the FDA classification of AXIOFILL), and the execution of the Sanara acquisition.
Investor Verification Checklist
- Sanara Acquisition Details: Verify the closing conditions, regulatory approvals, and integration risks associated with the $350 million acquisition of Sanara MedTech.
- Wound Segment Recovery: Assess the long-term impact of Medicare reimbursement changes on the Wound product line and the timeline for stabilization.
- Credit Quality: Review the specific legacy customers contributing to the $14.8 million allowance for credit losses and the likelihood of further write-offs.
- Debt Structure: Confirm the terms of the new $300 million Hayfin Term Loan and the impact of the Citizens Term Loan prepayment on liquidity.
- Regulatory Litigation: Monitor the status of the lawsuit against the FDA regarding the classification of AXIOFILL, which could impact future product sales.